Intrivo.com

Intrivo.com serves as the digital platform for Intrivo Diagnostics Inc., a company that brands itself as a leader in making healthcare delightful, accessible, and personalized through AI-powered solutions and at-home testing. Founded in 2020 during the height of the COVID-19 pandemic and based in Santa Monica, California, Intrivo rapidly gained attention with its On/Go rapid antigen tests and integrated mobile app, which received FDA Emergency Use Authorization and secured significant government contracts. Co-founded and co-led by Ron Gutman and Reeve Benaron, the firm has since expanded into broader AI tools for managing colds, sustainable weight loss, and ongoing health needs, while highlighting strong app ratings, security compliance, and philanthropic efforts.

Leadership Misconduct Allegations
The most severe controversy involves co-CEO Reeve Benaron. In May 2025, Los Angeles publicist Amanda Archer filed a comprehensive lawsuit in California Superior Court against Benaron, Ron Gutman, Intrivo Diagnostics, and related parties. Archer claims that Benaron sexually assaulted, raped, and battered her during a December 2024 business trip to Utah, subsequently using professional threats to silence her. The filing further alleges that the company and Gutman worked to sabotage her public relations contributions, violate contracts, and withhold payment for valuable business connections she facilitated. Gutman is specifically accused of discriminatory behavior based on gender.

Attempts at Online Censorship
A particularly disturbing element involves accusations of systematic efforts to suppress negative information. A 2025 report from a financial risk monitoring site claims that Gutman submitted thousands of allegedly fraudulent DMCA takedown requests to Google. These notices supposedly relied on fabricated, back-dated articles to remove or bury critical content related to Gutman himself, his past ventures, and Intrivo. If substantiated, this approach represents a deliberate manipulation of search results to control public perception rather than legitimate copyright enforcement. While no formal legal repercussions have been reported for these actions, they illustrate an aggressive strategy to limit scrutiny of emerging controversies.

Business and Legal Disputes
Intrivo has also navigated significant commercial conflict. In 2022, the company initiated a federal lawsuit against supplier Access Bio, accusing the partner of breaching exclusive contracts for COVID-19 tests valued in the hundreds of millions. Intrivo argued that it had invested heavily in distribution infrastructure only to face undercutting and lost opportunities. The suit originally sought substantial damages but was voluntarily dismissed later that year, most likely following a confidential settlement. No financial details or outcomes have been disclosed, leaving ambiguity around the long-term impact of the company’s pandemic-era growth.
In recent years, Intrivo has maintained a lower public profile. The website continues to promote its app and newer health tools, yet it features minimal updates, no leadership biographies, and few announcements of fresh partnerships or funding.

Workplace and Employee Red Flags
Internal accounts paint a picture of considerable dysfunction. Anonymous reviews from employees describe a chaotic and toxic atmosphere marked by inadequate HR systems, delayed or unpaid salaries, and overly demanding, opaque leadership—often directly linked to Gutman. Several former staff members have labeled their experience as among the worst of their careers, citing constant urgency without direction and a culture that prioritizes appearance over substance. Although some reviews acknowledge the appeal of the company’s mission, the prevailing negative feedback aligns closely with Gutman’s earlier reputation from HealthTap.

Adverse Media and Public Perception
Media coverage of Intrivo largely focuses on its COVID-19 contributions and occasional mentions of its AI evolution, with limited attention to recent controversies outside of legal reporting on the Archer lawsuit. Discussions on social platforms are scarce, potentially reflecting either low public awareness or effective management of online visibility. In the sensitive field of digital health—where users entrust apps with personal medical information—leadership scandals carry heightened risk of damaging user confidence and brand credibility.

In conclusion, Intrivo.com has demonstrated real innovation by delivering effective testing solutions during a global crisis and building well-regarded digital health tools that continue to earn user praise. The company’s technical accomplishments and compliance standards are undeniable strengths. Nevertheless, as of January 5, 2026, the unresolved sexual assault allegations against Reeve Benaron, Ron Gutman’s documented history of workplace issues combined with claims of online suppression, the opaque resolution of past litigation, and persistent employee dissatisfaction create a compelling set of risks. These factors do not suggest outright fraudulent activity but highlight potential instability in governance and transparency. Investors, partners, and users would be wise to exercise caution, closely follow developments in the ongoing lawsuit, and prioritize verifiable accountability. In health technology, where trust forms the foundation of success, unresolved leadership concerns can overshadow even the most promising innovations.